30-Jun-2011 - High-Tech Gründerfonds Management GmbH

Creathor Venture and High-Tech Gründerfonds accelerate growth of SIRION BIOTECH with further investment

In addition to Creathor Venture the investors High-Tech-Gründerfonds, KfW, and Bayernkapital also joined the current round to further fund the young Munich based biotech. SIRION’s core competence lies in the development and marketing of adenoviral and lentiviral vector technologies in the field of target validation.

A part of the new proceeds will be used to further promote already developed technologies and services. One focus will be an internationalization strategy to generate further clients in the EU and the US-market, where SIRION already has first prominent clients such as the FDA. In addition the funds will be used to further support the development of new vector-technologies that are essential for the vaccine-industry. First patents were filed in 2010 and cover a technology that will be essential for developing new vaccines against human Cytomegalo-Virus, Human Immundeficiency-Virus or Tuberculosis.

Karlheinz Schmelig, Partner at Creathor Venture states, that the the investment was made due to the current market situation and the recent results of the internal research activities: “SIRION was able to prove both a significant market need and demand for its products and showed that it is able to develop innovative products.”

This statement is somplemented by the management-team, Drs. Jürgen Flach (CEO) and Christian Thirion (CSO): „Due to the current round we will be able to raise the significant sales potential of our pipeline projects and launch new technologies in new markets such as the vaccine-market.

Facts, background information, dossiers
  • Sirion Biotech
  • High-Tech Gründerfo…
More about High-Tech Gründerfonds Management
  • News

    Tubulis Raises €10.7 M Series A

    Tubulis announced the close of a €10.7 million Series A financing round to accelerate the development of a new class of highly stable and efficient antibody-drug conjugates (ADCs) and to support the further growth of the company. The financing round was co-led by BioMedPartners and High-Tec ... more

    3D printer for medicine

    Kumovis, the developer of the world’s first 3D printer with clean room integration, announced that it has raised a €3.6 million Series A funding round. In Renolit SE and Solvay Ventures, the Munich-based start-up has found two additional partners on its way to establish industrial additive ... more

    €6 M to develop and launch a kit dedicated to sample preparation for single-cell RNA-sequencing

    Scipio bioscience, a Paris-based biotechnology company, developing a new generation of single-cell sequencing solutions, announces that it has secured a €6.0 M Series A financing from an international syndicate led by M Ventures (Amsterdam, The Netherlands), the corporate venture capital ar ... more

  • News

    SIRION Biotech Plans Opening of a New Office in the Boston Area

    SIRION Biotech announced its commitment to open a new office in the vicinity of Boston. The announcement was made during the 2015 BIO International Convention taking place in Philadelphia, Pennsylvania. SIRION is working with the Massachusetts Life Sciences Center (MLSC) to locate lab and o ... more

  • Companies


    SIRION Biotech is Europe's leading commercial supplier of viral vectors used for genetic cell modelling, gene target validation and gene therapy- and vaccination studies. Since its foundation in 2007, SIRION’s mission has been to change the paradigm for viral vector supplies. It has the ab ... more